Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors

Maselli, Daniele; Cortese, Bernardo; Ciabatti, Nicola; Gistri, Roberto; Levantino, Maurizio; Balbarini, Alberto; Caterina, Raffaele De; Petronio, Anna Sonia

doi:10.1016/j.ijcard.2007.02.005

Cited by 10 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased use of coronary stents and glycoprotein IIb/IIIa inhibitors has markedly reduced the incidence of emergent and urgent coronary artery bypass graft surgery for unsuccessful percutaneous coronary intervention [13]. Moreover, a number of studies demonstrated that the use of tirofiban after unsuccessful percutaneous coronary angioplasty does not increase the incidence of bleeding after urgent coronary artery bypass operations [14][15]. However, no previous studies of the impact of tirofiban on myocardial performance after heart surgery are currently available.…”

Section: Discussionmentioning

confidence: 99%

Effect of Preoperative Tirofiban on Postoperative Myocardial Performance in Patients With Left Main Coronary Artery Disease Undergoing Cabg Surgery

et al. 2014

View full text Add to dashboard Cite

Aim. In this study, we investigated the impact of tirofiban on ventricular performance in patients who were diagnosed with acute coronary syndrome, found to have left main coronary artery stenosis during coronary angiography, and administered tirofiban prior to coronary artery bypass to prevent the recurrence of an acute coronary syndrome during the preoperative period. Material and methods. The patients were divided into two groups. Group 1 included patients who were pre-diagnosed with acute coronary syndrome and administered tirofiban infusion in another hospital and subsequently sent to our center for advanced examination and treatment, where they exhibited left main coronary artery disease during coronary angiography and were submitted to surgery (n=28). Group 2 included patients who arrived at our emergency service with chest pain, were pre-diagnosed with acute coronary syndrome in the cardiology clinic, exhibited left main coronary artery disease during coronary angiography, and were submitted to urgent surgery without receiving tirofiban infusion (n=29). Standard and tissue Doppler echocardiography were applied to each patient in the preoperative and postoperative periods. Results. After bypass surgery, the mean postoperative left ventricular myocardial performance index (0.84±0.30) was significantly lower than the mean preoperative left ventricular myocardial performance index (1.10±0.35) (p=0.001). The left lateral myocardial performance index was lower in group 1 (0.76±0.31) than in group 2 (0.92±0.27) (p=0.050*), but the ejection fraction was higher in group 1 (61.46±7.74) than in group 2 (52.87±11.64) (p=0.003*). Conclusion. Preoperative administration of tirofiban improved postoperative left ventricular performance compared to pretreatment with aspirin alone in patients with left main coronary artery disease undergoing coronary artery bypass surgery. Therefore, we recommend the preoperative administration of tirofiban as an antithrombotic agent to patients who are undergoing coronary artery bypass for left main coronary artery disease. Цель. В этой работе изучено влияние тирофибана на желудочковые показа-тели у больных, которым был поставлен диагноз «острый коронарный син-дром» (ОКС), обнаружен стеноз левой коронарной артерии при коронарной ангиографии и введен тирофибан до операции коронарного шунтирования, чтобы не допустить повторения ОКС в предоперационном периоде. Материал и методы. Больные были разделены на две группы. В группу 1 были включены пациенты, которым был предварительно поставлен диагноз ОКС, введен тирофибан в другой больнице; затем они были направлены в наш центр, им было проведены современное обследование и лечение, под-твержден стеноз левой коронарной артерии при коронарной ангиографии, и пациенты были отправлены на хирургическое лечение (n=28). 2 группа -пациенты, доставленные в наш центр бригадами экстренной помощи, с болью в области груди; им был предварительно поставлен диагноз ОКС в клинике кардиологии, подтвержден стеноз левой коронарной артерии при коронарной ангиографии,...

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Preoperative Tirofiban on Postoperative Myocardial Performance in Patients With Left Main Coronary Artery Disease Undergoing Cabg Surgery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Severe thrombocytopenia (platelet count <20,000/μL) occurred in approximately 0.7% of patients receiving abciximab for the first time, more often than with either eptifibatide or tirofiban (0.2%). 375 A pooled analysis of 8 placebo-controlled studies concluded that abciximab, but not eptifibatide or tirofiban, increased the incidence of thrombocytopenia in patients also treated with heparin. 375 …”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

“…375 A pooled analysis of 8 placebo-controlled studies concluded that abciximab, but not eptifibatide or tirofiban, increased the incidence of thrombocytopenia in patients also treated with heparin. 375 …”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition)

Narouze

Benzon

Provenzano³

et al. 2017

Regional Anesthesia and Pain Medicine

118

View full text Add to dashboard Cite

The American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 survey of meeting attendees showed that existing ASRA anticoagulation guidelines for regional anesthesia were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors required separate guidelines for pain and spine procedures. In response, a guidelines committee was formed. After preliminary review of published complications reports and studies, the committee stratified interventional spine and pain procedures according to potential bleeding risk: low-, intermediate-, and high-risk procedures. The ASRA regional anesthesia anticoagulation guidelines were largely deemed appropriate for the low- and intermediate-risk categories, but the high-risk category required further investigation. The first guidelines specific to interventional spine and pain procedures were published in 2015. Recent reviews evaluating bleeding complications in patients undergoing specific interventional pain procedures, the development of new regional anesthesia and acute pain guidelines, and the development of new anticoagulants and antiplatelet medications necessitate complementary updated guidelines. The authors desired coordination with the authors of the recently updated regional and acute pain anticoagulation guidelines. The latest evidence was sought through extensive database search strategies and the recommendations were evidence based when available and pharmacology driven otherwise. We could not provide strength and grading of these recommendations because there are not enough well-designed large studies concerning interventional pain procedures to support such grading. Although the guidelines could not always be based on randomized studies or on large numbers of patients from pooled databases, it is hoped that they will provide sound recommendations and the evidentiary basis for such recommendations. This publication is intended as a living document to be updated periodically with consideration of new evidence.

show abstract

“…331 Although the data are inconsistent, increased perioperative bleeding in patients undergoing cardiac and vascular surgery after receiving GPIIb/IIIa antagonists has been noted. 337 In general, the cardiac surgical and interventional radiology literature recommend that elective surgery be delayed 24 to 48 hours after abciximab and 4 to 8 hours after eptifibatide or tirofiban. For semiurgent surgery, if possible, delay until the antiplatelet effects have significantly dissipated (approximately 12-24 hours for abciximab, and 4-6 hours for peptidomimetic agents like eptifibatide or tirofiban) is advocated.…”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

“…335 Surgery performed within 12 hours of abciximab administration will most likely necessitate a platelet transfusion as has been shown in patients having coronary artery bypass grafting. 337 Although rare, abciximab, eptifibatide, and tirofiban can produce thrombocytopenia immediately after drug administration in a small proportion of patients. Reactions usually occur within hours but may occasionally be delayed.…”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Narouze

Benzon

Provenzano³

et al. 2015

Regional Anesthesia and Pain Medicine

267

View full text Add to dashboard Cite

Interventional spine and pain procedures cover a far broader spectrum than those for regional anesthesia, reflecting diverse targets and goals. When surveyed, interventional pain and spine physicians attending the American Society of Regional Anesthesia and Pain Medicine (ASRA) 11th Annual Pain Medicine Meeting exhorted that existing ASRA guidelines for regional anesthesia in patients on antiplatelet and anticoagulant medications were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors necessitated separate guidelines for pain and spine procedures. In response, ASRA formed a guidelines committee. After preliminary review of published complication reports and studies, committee members stratified interventional spine and pain procedures according to potential bleeding risk as low-, intermediate-, and high-risk procedures. The ASRA guidelines were deemed largely appropriate for the low- and intermediate-risk categories, but it was agreed that the high-risk targets required an intensive look at issues specific to patient safety and optimal outcomes in pain medicine. The latest evidence was sought through extensive database search strategies and the recommendations were evidence-based when available and pharmacology-driven otherwise. We could not provide strength and grading of these recommendations as there are not enough well-designed large studies concerning interventional pain procedures to support such grading. Although the guidelines could not always be based on randomized studies or on large numbers of patients from pooled databases, it is hoped that they will provide sound recommendations and the evidentiary basis for such recommendations.

show abstract

Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors

Cited by 10 publications

References 42 publications

Effect of Preoperative Tirofiban on Postoperative Myocardial Performance in Patients With Left Main Coronary Artery Disease Undergoing Cabg Surgery

Effect of Preoperative Tirofiban on Postoperative Myocardial Performance in Patients With Left Main Coronary Artery Disease Undergoing Cabg Surgery

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition)

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Contact Info

Product

Resources

About